Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[WT 1 and leukemia]

K Inoue1, H Sugiyama

  • 1Department of Medicine III, Osaka University Medical School.

[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology
|June 1, 1995
PubMed
Summary
This summary is machine-generated.

WT1 gene expression is significant in acute leukemia and inversely correlates with prognosis, aiding in minimal residual disease detection. WT1 levels are low in non-Hodgkin's lymphoma, unlike in leukemia.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term follow-up of minimal residual disease in leukemia patients by monitoring WT1 (Wilms tumor gene) expression levels.

Blood·1996
Same author

Differential selectivity of M1 and M3 type muscarinic acetylcholine receptors in coupling with a G protein G01 alpha examined in Xenopus oocytes.

Neuroscience letters·1996
Same author

Catalytic activities of hammerhead ribozymes with a triterpenoid linker instead of stem/loop II.

FEBS letters·1996
Same author

Interleukin-6-mediated growth enhancement of cell lines derived from pyothorax-associated lymphoma.

Laboratory investigation; a journal of technical methods and pathology·1996
Same author

p70 S6 kinase sensitivity to rapamycin is eliminated by amino acid substitution of Thr229.

Journal of immunology (Baltimore, Md. : 1950)·1996
Same author

[Role of apoptosis in renal injury].

Nihon rinsho. Japanese journal of clinical medicine·1996
Same journal

[Rinsho ketsueki] The Japanese journal of clinical hematology·2026
Same journal

[Rinsho ketsueki] The Japanese journal of clinical hematology·2026
Same journal

[Rinsho ketsueki] The Japanese journal of clinical hematology·2026
Same journal

[Recent advances in pathogenesis, diagnosis, and therapeutic strategies for POEMS syndrome].

[Rinsho ketsueki] The Japanese journal of clinical hematology·2026
Same journal

[Recent advances in management of systemic AL amyloidosis].

[Rinsho ketsueki] The Japanese journal of clinical hematology·2026
Same journal

[Treatment strategies for relapsed or refractory multiple myeloma: proposals for optimal treatment sequencing].

[Rinsho ketsueki] The Japanese journal of clinical hematology·2026
See all related articles

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Context:

  • Wilms' tumor suppressor gene WT1's role in other hematologic malignancies is explored.
  • Investigates WT1 gene expression in acute leukemia, chronic myelogenous leukemia (CML), and non-Hodgkin's lymphoma (NHL).
  • Examines WT1 gene mutations in acute leukemia patients.

Purpose:

  • To assess WT1 gene expression levels in various hematologic cancers.
  • To determine the correlation between WT1 expression and clinical phase or prognosis in leukemia.
  • To evaluate WT1 as a marker for minimal residual disease (MRD) detection in acute leukemia.

Summary:

  • WT1 gene expression was significantly elevated in all acute leukemia and CML patients, increasing with CML progression.
  • WT1 expression was markedly low or undetectable in NHL, with no point mutations found in WT1 in acute leukemia.

Related Experiment Videos

  • WT1 gene expression inversely correlated with acute leukemia prognosis and effectively detected MRD, comparable to specific DNA markers.

    • Impact:

    • WT1 gene expression serves as a valuable prognostic indicator in acute leukemia.
    • Quantification of WT1 expression enables sensitive detection of minimal residual disease (MRD) in acute leukemia.
    • WT1 expression levels can guide treatment strategies and monitoring for hematologic malignancies.